COVID-19

The death toll from the coronavirus will place COVID-19 in the top 10 causes of death in the United States in 2020, possibly as high as #3. Yet, it likely will remain far behind the deaths caused by heart disease and cancer.
After months of speculation, the results of the first placebo-controlled trial of remdesivir are out. The drug does help people with COVID-19 disease, but it's nothing to get excited about. Here's why.
COVID-19 has exposed fault lines in our healthcare system, often problems that physicians and nurses have been pointing out, to no avail, for years. New York City's mayor announced a plan to modify grading due to COVID-19 ignoring the fact that many of the school's graduates have significant functional illiteracies. The courts in Michigan are finally stepping up to address the real issues. Miasma is responsible for COVID-19's infectability. And finally, reshaping the economy involves more than a stronger safety net.
The first data from the SIMPLE trial of remdesivir has been released by Gilead. Even though this is the first complete trial of the drug, it doesn't answer many questions. That's because there was no control group – something that would have been unethical for the trial participants since they had severe disease. We're just getting started.
Much remains unknown about the coronavirus. A new paper published in The Lancet estimates that roughly 60% of the population needs to be immune to COVID-19 to achieve herd immunity.
The general belief is that COVID-19’s harms fall disproportionately upon the frail, as well as the classes and groups that often find themselves holding the short end of the stick: the poor and minorities. What makes these groups so susceptible? Let's take a look.
Many politicians insist that they will "follow the science" in regard to reopening the economy. But the COVID-19 pandemic has placed us in uncharted territory with few relevant precedents to guide policymaking. Therefore, "Follow the science," is indistinguishable from, "Do what I say." This doesn't prevent activist websites like Undark from smearing reputable scientists who speak out in disagreement.
What's worse, flying American Airlines or camping out in a Greyhound's bus bathroom during National Projectile Vomiting Day? Ask Erin Strine. American recently stuffed her, and a whole bunch of other people, into a flying incubator. It wasn't pretty.
New York's Mount Sinai hospital reports that several patients under age 50 have suffered from COVID-19-associated strokes from blood clots. Other anecdotal and small-series reports have shown increased clotting in COVID-19 patients, often ending in death. What's going on here? Let's take a look.
Being anti-science and anti-technology is a luxury for when times are good. In times of crisis, people beg for help from scientists, doctors, and pharmaceutical companies.
When it comes to unwinding the lockdown, we are faced with the urge to be social once again. And since we are also faced with huge uncertainty, what does "an abundance of caution" actually mean?
Preliminary data, obtained from a randomized clinical trial of remdesivir in China, look bad. Maybe even very bad. But this doesn't mean that the drug won't be shown to be useful in other trials. Nonetheless, not good news.